#India Piperacillin/Tazobactam Market

[cpharmaceutical]

Causes and Risk Factors

Some bacteria cause illness. They invade and quickly multiply in the body to form colonies. When this happens in the respiratory tract, the following diseases may occur:

1. Pharyngitis -- Streptococcus pyogenes

2. Diphtheria -- Corynebacterium diphtheria

3. Pertussis -- Bordetella pertussis

4. Tuberculosis -- Mycobacterium tuberculosis

Gastrointestinal infections caused by bacteria include:

1. Peptic ulcers -- Helicobacter pylori

2. Enteric (typhoid) fever -- Salmonella typhi

3. Gastroenteritis -- Shigella, Salmonella, and Escherichia coli

Bacteria cause infections of the nervous system such as:

1. Meningitis -- Streptococcus pneumonia and Neisseria meningitidis

2. Tetanus -- Clostridium tetani

3. Botulism -- Clostridium botulinum

Urogenital infections caused by bacteria include:

1. Urinary tract infections -- Escherichia coli

2. Gonorrhea -- Neisseria gonorrhoeae

3. Chlamydia -- Chlamydia trachomatis

4. Syphilis -- Treponema pallidum

Bacteria also cause skin infections such as:

1. Leprosy -- Mycobacterium leprae

2. Abscess -- Staphylococcus aureus

Signs and Symptoms

The symptoms of bacterial infection would depend on the condition, the organ affected, and the kind of bacteria causing the infection.

Investigations

The diagnosis of bacterial infections would depend on the symptomatic history of the patient. The tests that may be done include:

1. Physical examination

2. Blood tests

3. Urine tests

4. Urine culture

5. Gram stain to identify bacteria

6. Toxin assay to look for the toxins made by the bacteria

7. Culture or biopsy of the tissue infected

Treatment

The treatment will depend on the kind of infection. Antibiotics are usually prescribed to treat bacterial infections. These are medicines that kill the bacteria. They may be given in the oral or injectable form. Some antibiotics that may be prescribed for a bacterial infection may include:

1. Amoxicillin

2. Azithromycin

3. Doxycycline

4. Ofloxacin

5. Tetracycline

6. Gentamycin

7. Metronidazole

8. Clindamycin

Supportive therapy may be required for other symptoms, such as fever.

Complications and When Should You See a Doctor

The complications will depend on the kind of bacterial infection.

Antibiotics must be taken carefully and for the duration, they are prescribed for. Taking them too frequently, taking them without a prescription or not completing the full course of treatment may lead to a development of antibiotic resistance, where antibiotics fail to kill bacteria.

Antibiotic resistance makes treatment of bacterial infections difficult and may prolong the illness and severity.

References

Fernández-Frackelton M. Bacteria. In: Walls RM, Hockberger RS, Gausche-Hill M, eds. Rosen's Emergency Medicine: Concepts and Clinical Practice. 9th ed. Philadelphia, PA:Elsevier; 2018:chap 121.

McAdam AJ, Milner DA, Sharpe AH. Infectious diseases. In: Kumar V, Abbas AK, Aster JC, eds. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 8.

Benefits of PIPTO Injection

In Bacterial infections

PIPTO Injection contains two different medicines that work together to kill the bacteria that cause infections. Piperacillin belongs to a group of medicines called penicillins that work by stopping the growth of bacteria. Tazobactam is a beta-lactamase inhibitor that reduces resistance and enhances the activity of Piperacillin against bacteria.

Side effects of PIPTO Injection

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of PIPTO

Nausea

Vomiting

Diarrhea

Rash

Allergic reaction

How to use PIPTO Injection

Your doctor or nurse will give you this medicine. Kindly do not self administer.

How PIPTO Injection works

PIPTO Injection is a combination of two medicines: Piperacillin and Tazobactum. Piperacillin is an antibiotic. It works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria. Tazobactum is a beta-lactamase inhibitor which reduces resistance and enhances the activity of Piperacillin against bacteria.

Safety advice

Alcohol

SAFE

Consuming alcohol with PIPTO Injection does not cause any harmful side effects.

Pregnancy

SAFE IF PRESCRIBED

PIPTO Injection is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.

Breast feeding

SAFE IF PRESCRIBED

PIPTO Injection is safe to use during breastfeeding. Human studies suggest that the drug does not pass into the breastmilk in a significant amount and is not harmful to the baby.

Driving

CONSULT YOUR DOCTOR

It is not known whether PIPTO Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

Kidney

CAUTION

PIPTO Injection should be used with caution in patients with kidney disease. Dose adjustment of PIPTO Injection may be needed. Please consult your doctor.

Liver

SAFE IF PRESCRIBED

PIPTO Injection is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of PIPTO Injection may not be needed in these patients. Please consult your doctor.

What if you forget to take PIPTO Injection?

If you miss a dose of PIPTO Injection, please consult your doctor.

[chemanalysta]

Piperacillin Tazobactam Prices in the Global Market

In the Asia-Pacific region, Piperacillin Tazobactam prices achieved robust gains with the start of the fourth quarter of 2022. The Ex-Vapi prices for Piperacillin & Tazobactam in India increased by 1.8% in October. As in the first week of October, the Long week holiday affected the production activities in factories resulting in tight supply in the domestic market. However, the prices in India started to follow a downtrend and decreased by around 1.8% in the second half of the quarter. Covid cases resurgence from the end of October led to both logistic restriction and end-user run rate limitation, which resulted in Piperacillin & Tazobactam inventory accumulation and lower offers. The impact of the epidemic ebbed away the demand, leading to some manufacturers opting to slow production. Additionally, export orders from the international market were sluggish due to dull market dynamics.

[techsciresearch]

India Piperacillin/Tazobactam Market to Grow at a Substantial Rate During the Forecast Period | TechSci Research

Growing prevalence of bacterial infections is expected to drive the growth of India Piperacillin/Tazobactam market during the forecast period.

According to TechSci Research report, “India Piperacillin/Tazobactam Market By Route of Administration (Intravenous injection v/s Intramuscular injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By Application (Intra-abdominal infections, Nosocomial Pneumonia, Skin and Skin Structure Infections, Community Acquired Pneumonia and Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2027”, the India piperacillin/tazobactam market is expected to grow at a substantial rate during the forecast period on account of its suitability for the treatment of urinary tract infections. Piperacillin and tazobactam injections are used for the treatment of appendicitis in adults and pediatric patients, which in turn is expected to drive the market growth during the forecast period.

Additionally, uncomplicated as well as complicated skin and skin structure infections, such as cellulitis, ischemic/diabetic foot infections, etc. are known to be well treated by this API drug which is projected to boost the growth of India piperacillin/tazobactam Market. Also, side effects observed due to consumption of piperacillin/tazobactam include headache, trouble sleeping, rash, nausea, constipation, and diarrhea, among others, which can act as impediment to the market growth over the coming years. Additionally, piperacillin/tazobactam is suitable to treat intra-abdominal infections which is further estimated to accelerate the market growth during the forecast period.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "India Piperacillin/Tazobactam Market"

https://www.techsciresearch.com/report/india-piperacillin-tazobactam-market/7296.html

The India piperacillin/tazobactam market is segmented based on route of administration, distribution channel, source, application, end user, company, and region. In terms of application, the market is fragmented into intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, community acquired pneumonia and others. Out of which, the nosocomial pneumonia is expected to dominate the market in the next 5 years which can be attributed to effectiveness of this drug in treating nosocomial pneumonia.

Based on route of administration, the market can be segmented into intramuscular and intravenous. The intravenous route of administration is expected to dominate the market in the coming years on account of certain advantages it offers such rapid response, and easily control over the dosage of the drug. Furthermore, intravenous route of administration is much useful in situations of poor gastrointestinal absorption, which is further forecast to contribute to the growth of the segment.

Aristo Pharmaceuticals Ltd, Radicura Pharmaceuticals Pvt. Ltd., Tauras Laboratories Pvt. Ltd., Taj Pharmaceuticals Ltd., Corona Remedies Pvt. Ltd., Bestochem Formulations (India) Pvt. Ltd., Alpa Laboratories Ltd., Medical Pharma Ltd., Cipla Ltd., Lupin Laboratories Ltd and others are some of the leading players operating in India piperacillin/tazobactam market. Companies operating in the market are using organic strategies such as product launches, mergers and acquisitions, research collaborations to boost their share.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7296

Customers can also request for 10% free customization on this report.

“India piperacillin/tazobactam market is expected to witness substantial growth during the forecast period on account of the rising initiatives by the government of the country for API manufacturing and drug development. Additionally, piperacillin/tazobactam API is used in intensive care medicine (pneumonia, peritonitis) which is further expected to fuel the market growth through FY2027. Growing prevalence of skin and tissue infections amongst population is forecast to bolster to demand for piperacillin/tazobactam in the market over the next 5 years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“India Piperacillin/Tazobactam Market By Route of Administration (Intravenous injection v/s Intramuscular injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By Application (Intra-abdominal Infections, Nosocomial Pneumonia, Skin and Skin Structure Infections, Community Acquired Pneumonia and Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2027”, has evaluated the future growth potential of India piperacillin/tazobactam market and provides statistics & information on market size, structure and future market growth.

The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India piperacillin/tazobactam market.

Browse Related Reports:

Global Hydroxychloroquine and Chloroquine Market By Type (Injectables & Tablets), By Route of Administration (Oral v/s Intravenous), By Strength (100mg, 250mg & 500mg), By Application (Rheumatoid Arthritis, Malaria, COVID-19, Others), By Region, Competition, Forecast & Opportunities, 2030

https://www.techsciresearch.com/report/chloroquine-and-hydroxychloroquine-market/4609.html

Global Immunosuppressants API Market By Method (Synthetic Chemistry, Peptide Chemistry, Fermentation, Chromatographic Purification), By Application (Autoimmune Disease, Organ Transplant), By Type (Corticosteroids, Janus Kinase Inhibitor, Calcineurin Inhibitors, mTOR Inhibitor, Others), By Product (Tablets, Capsules, Liquids, Injections), By APIs (Tacrolimus, Sirolimus, Everolimus, Mycophenolate Mofetil, Mycophenolate Sodium), By End User (Biotechnology & Biopharmaceutical Companies, CMOs, CROs, CDMOs, Others), By Region, Competition, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/immunosuppressants-api-market/4673.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For more market research blogs visit: https://techsciblog.com/

[techscimarketresearch]

India Piperacillin/Tazobactam Market to Grow at a Substantial Rate During the Forecast Period | TechSci Research

Growing prevalence of bacterial infections is expected to drive the growth of India Piperacillin/Tazobactam market during the forecast period.

According to TechSci Research report, “India Piperacillin/Tazobactam Market By Route of Administration (Intravenous injection v/s Intramuscular injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By Application (Intra-abdominal infections, Nosocomial Pneumonia, Skin and Skin Structure Infections, Community Acquired Pneumonia and Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2027”, the India piperacillin/tazobactam market is expected to grow at a substantial rate during the forecast period on account of its suitability for the treatment of urinary tract infections. Piperacillin and tazobactam injections are used for the treatment of appendicitis in adults and pediatric patients, which in turn is expected to drive the market growth during the forecast period.

Additionally, uncomplicated as well as complicated skin and skin structure infections, such as cellulitis, ischemic/diabetic foot infections, etc. are known to be well treated by this API drug which is projected to boost the growth of India piperacillin/tazobactam Market. Also, side effects observed due to consumption of piperacillin/tazobactam include headache, trouble sleeping, rash, nausea, constipation, and diarrhea, among others, which can act as impediment to the market growth over the coming years. Additionally, piperacillin/tazobactam is suitable to treat intra-abdominal infections which is further estimated to accelerate the market growth during the forecast period.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "India Piperacillin/Tazobactam Market"

https://www.techsciresearch.com/report/india-piperacillin-tazobactam-market/7296.html

The India piperacillin/tazobactam market is segmented based on route of administration, distribution channel, source, application, end user, company, and region. In terms of application, the market is fragmented into intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, community acquired pneumonia and others. Out of which, the nosocomial pneumonia is expected to dominate the market in the next 5 years which can be attributed to effectiveness of this drug in treating nosocomial pneumonia.

Based on route of administration, the market can be segmented into intramuscular and intravenous. The intravenous route of administration is expected to dominate the market in the coming years on account of certain advantages it offers such rapid response, and easily control over the dosage of the drug. Furthermore, intravenous route of administration is much useful in situations of poor gastrointestinal absorption, which is further forecast to contribute to the growth of the segment.

Aristo Pharmaceuticals Ltd, Radicura Pharmaceuticals Pvt. Ltd., Tauras Laboratories Pvt. Ltd., Taj Pharmaceuticals Ltd., Corona Remedies Pvt. Ltd., Bestochem Formulations (India) Pvt. Ltd., Alpa Laboratories Ltd., Medical Pharma Ltd., Cipla Ltd., Lupin Laboratories Ltd and others are some of the leading players operating in India piperacillin/tazobactam market. Companies operating in the market are using organic strategies such as product launches, mergers and acquisitions, research collaborations to boost their share.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7296

Customers can also request for 10% free customization on this report.

“India piperacillin/tazobactam market is expected to witness substantial growth during the forecast period on account of the rising initiatives by the government of the country for API manufacturing and drug development. Additionally, piperacillin/tazobactam API is used in intensive care medicine (pneumonia, peritonitis) which is further expected to fuel the market growth through FY2027. Growing prevalence of skin and tissue infections amongst population is forecast to bolster to demand for piperacillin/tazobactam in the market over the next 5 years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“India Piperacillin/Tazobactam Market By Route of Administration (Intravenous injection v/s Intramuscular injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By Application (Intra-abdominal Infections, Nosocomial Pneumonia, Skin and Skin Structure Infections, Community Acquired Pneumonia and Others), By End User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2027”, has evaluated the future growth potential of India piperacillin/tazobactam market and provides statistics & information on market size, structure and future market growth.

The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India piperacillin/tazobactam market.

Browse Related Reports:

Global Hydroxychloroquine and Chloroquine Market By Type (Injectables & Tablets), By Route of Administration (Oral v/s Intravenous), By Strength (100mg, 250mg & 500mg), By Application (Rheumatoid Arthritis, Malaria, COVID-19, Others), By Region, Competition, Forecast & Opportunities, 2030

https://www.techsciresearch.com/report/chloroquine-and-hydroxychloroquine-market/4609.html

Global Immunosuppressants API Market By Method (Synthetic Chemistry, Peptide Chemistry, Fermentation, Chromatographic Purification), By Application (Autoimmune Disease, Organ Transplant), By Type (Corticosteroids, Janus Kinase Inhibitor, Calcineurin Inhibitors, mTOR Inhibitor, Others), By Product (Tablets, Capsules, Liquids, Injections), By APIs (Tacrolimus, Sirolimus, Everolimus, Mycophenolate Mofetil, Mycophenolate Sodium), By End User (Biotechnology & Biopharmaceutical Companies, CMOs, CROs, CDMOs, Others), By Region, Competition, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/immunosuppressants-api-market/4673.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For more market research blogs visit: https://techsciblog.com/

[newestbalance]

Another antibiotic crisis: fragile supply leads to shortages

LONDON (Reuters) – Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fuelling the evolution of “superbugs” that do not respond to modern medicines, according to a new report on Thursday.

FILE PHOTO: A technician stocks the shelves of a pharmacy in Kentucky, February 2018. REUTERS/Bryan Woolston/File Photo

The non-profit Access to Medicine Foundation (AMF) said there was an emerging crisis in the global anti-infectives market as fragile drug supply chains – reliant on just a few big suppliers – come close to collapse.

The result is shortages of products like piperacillin-tazobactam, an antibiotic combination used intravenously in intensive care, which has been in tight supply since a 2016 explosion at a Chinese pharmaceutical ingredients factory.

Another antibiotic, benzathine penicillin G (BPG), faces shortages in at least 39 countries, including Germany and Brazil.

BPG is a key drug for preventing transmission of syphilis from mother to child and the shortage frustrated Brazil’s efforts to bring a disease outbreak under control between 2012 and 2015. BPG is also used to fight rheumatic heart disease.

In absence of the right drugs, patients may take less effective or poor quality medicines that increase the risk of antimicrobial resistance developing.

“Things are getting worse because the market is not fixing the problem, despite the expansion in the need for such specialist antibiotics,” said AMF Executive Director Jayasree Iyer.

Global demand for antibiotics has grown by two-thirds since 2000, driven by population growth and the need for medicines to fight infectious diseases in low- and middle-income countries.

Most antibiotics are cheap, off-patent generic medicines, which is good for affordability. But that also means they have very low profit margins – particularly compared to modern drugs for diseases like cancer – offering manufacturers little incentive to invest in new production facilities.

The rise in shortages has gone hand in hand with a wave of consolidation among the companies making generic drugs – which range from global pharmaceutical giants to smaller firms in countries such as India – reducing the number of suppliers making individual product lines.

Sporadic drug shortages are not unique to antibiotics. Recently, for example, there has been a worldwide shortage of Mylan’s (MYL.O) market-leading EpiPen emergency allergy device.

But antibiotic shortages can have especially dire consequences, since doctors have to resort to sub-optimal treatments that are less efficient at killing specific pathogens, leading to the rise of resistant bacteria or so-called superbugs.

An estimated 70 percent of bacteria are already resistant to at least one antibiotic that is commonly used to treat them, making the evolution of such superbugs one of the biggest threats facing medicine today.

Reporting by Ben Hirschler; Editing by Mark Potter

The post Another antibiotic crisis: fragile supply leads to shortages appeared first on World The News.

from World The News https://ift.tt/2J7LyBC via Everyday News

[dani-qrt]

Another antibiotic crisis: fragile supply leads to shortages

LONDON (Reuters) – Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fuelling the evolution of “superbugs” that do not respond to modern medicines, according to a new report on Thursday.

FILE PHOTO: A technician stocks the shelves of a pharmacy in Kentucky, February 2018. REUTERS/Bryan Woolston/File Photo

The non-profit Access to Medicine Foundation (AMF) said there was an emerging crisis in the global anti-infectives market as fragile drug supply chains – reliant on just a few big suppliers – come close to collapse.

The result is shortages of products like piperacillin-tazobactam, an antibiotic combination used intravenously in intensive care, which has been in tight supply since a 2016 explosion at a Chinese pharmaceutical ingredients factory.

Another antibiotic, benzathine penicillin G (BPG), faces shortages in at least 39 countries, including Germany and Brazil.

BPG is a key drug for preventing transmission of syphilis from mother to child and the shortage frustrated Brazil’s efforts to bring a disease outbreak under control between 2012 and 2015. BPG is also used to fight rheumatic heart disease.

In absence of the right drugs, patients may take less effective or poor quality medicines that increase the risk of antimicrobial resistance developing.

“Things are getting worse because the market is not fixing the problem, despite the expansion in the need for such specialist antibiotics,” said AMF Executive Director Jayasree Iyer.

Global demand for antibiotics has grown by two-thirds since 2000, driven by population growth and the need for medicines to fight infectious diseases in low- and middle-income countries.

Most antibiotics are cheap, off-patent generic medicines, which is good for affordability. But that also means they have very low profit margins – particularly compared to modern drugs for diseases like cancer – offering manufacturers little incentive to invest in new production facilities.

The rise in shortages has gone hand in hand with a wave of consolidation among the companies making generic drugs – which range from global pharmaceutical giants to smaller firms in countries such as India – reducing the number of suppliers making individual product lines.

Sporadic drug shortages are not unique to antibiotics. Recently, for example, there has been a worldwide shortage of Mylan’s (MYL.O) market-leading EpiPen emergency allergy device.

But antibiotic shortages can have especially dire consequences, since doctors have to resort to sub-optimal treatments that are less efficient at killing specific pathogens, leading to the rise of resistant bacteria or so-called superbugs.

An estimated 70 percent of bacteria are already resistant to at least one antibiotic that is commonly used to treat them, making the evolution of such superbugs one of the biggest threats facing medicine today.

Reporting by Ben Hirschler; Editing by Mark Potter

The post Another antibiotic crisis: fragile supply leads to shortages appeared first on World The News.

from World The News https://ift.tt/2J7LyBC via Online News

[chemanalysta]

In the Asia-Pacific region, Piperacillin Tazobactam prices achieved robust gains with the start of the fourth quarter of 2022. The Ex-Vapi prices for Piperacillin & Tazobactam in India increased by 1.8% in October. As in the first week of October, the Long week holiday affected the production activities in factories resulting in tight supply in the domestic market. However, the prices in India started to follow a downtrend and decreased by around 1.8% in the second half of the quarter. Covid cases resurgence from the end of October led to both logistic restriction and end-user run rate limitation, which resulted in Piperacillin & Tazobactam inventory accumulation and lower offers. The impact of the epidemic ebbed away the demand, leading to some manufacturers opting to slow production. Additionally, export orders from the international market were sluggish due to dull market dynamics.

[chemanalysta]

In the Asia-Pacific region, Piperacillin Tazobactam prices achieved robust gains with the start of the fourth quarter of 2022. The Ex-Vapi prices for Piperacillin & Tazobactam in India increased by 1.8% in October. As in the first week of October, the Long week holiday affected the production activities in factories resulting in tight supply in the domestic market. However, the prices in India started to follow a downtrend and decreased by around 1.8% in the second half of the quarter. Covid cases resurgence from the end of October led to both logistic restriction and end-user run rate limitation, which resulted in Piperacillin & Tazobactam inventory accumulation and lower offers. The impact of the epidemic ebbed away the demand, leading to some manufacturers opting to slow production. Additionally, export orders from the international market were sluggish due to dull market dynamics.

[techscimarketresearch]

According to TechSci Research report, the India piperacillin/tazobactam market is expected to grow at a substantial rate during the forecast period on account of its suitability for the treatment of urinary tract infections.

Go through the whole news @ https://bit.ly/39rQXCI |

Contact us at: Tel: +1-646-360-1656 | Email: sales@techsciresearch.com